• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology

Posted on: Tuesday, 2 December 2008, 07:00 CST

ST. JOSEPH, Mich., Dec. 2 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Burnham has become a certified GeneGo Center of Excellence. Burnham researchers will have institution-wide access to GeneGo's MetaCore data analysis suite, training and advanced support. The Burnham institute is a world-class biomedical research facility running multiple OMICs experimental studies throughout many departments, including research in cancer, stem cells, and neurobiology. MetaCore will provide a central data repository, management and collaboration platform integrated with a manually curated knowledge base and tools for seamless analyses of these studies.

"Burnham is in our backyard and we are very pleased to welcome them as a new GeneGo customer and Center of Excellence," said Julie Bryant, GeneGo's VP of Business development. "Stem cells, chemical biology, and disease specific pathway analysis platforms are among our research priorities and we are looking forward to a long term productive partnership."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.1(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.1(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

SOURCE GeneGo, Inc.

Source: PR Newswire

More News in this Category